Tumor lysis syndrome in a multiple myeloma treated with thalidomide [1]

Annals of Oncology

Volumn 15, Issue 3, 2004, Pages 537-

  Feunte, N ^a   Mane J M ^a   Barcelo, R ^a   Munoz A ^a   Perez Hoyos, T ^a   Lopez Vivanco, G ^a  

^a HOSPITAL DE CRUCES   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; BICARBONATE; CALCIUM ION; CREATININE; DEXAMETHASONE; DOXORUBICIN; FUROSEMIDE; MELPHALAN; PHOSPHORUS; POTASSIUM ION; THALIDOMIDE; URIC ACID; VINCRISTINE;

ACUTE KIDNEY FAILURE; ADULT; ANURIA; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER STAGING; CASE REPORT; CREATININE BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG MEGADOSE; HUMAN; HYPERKALEMIA; HYPERPHOSPHATEMIA; HYPERURICEMIA; LETTER; MALE; MULTIPLE MYELOMA; OSTEOLYSIS; PLASMACYTOMA; PRIORITY JOURNAL; SIDE EFFECT; TUMOR LYSIS SYNDROME;

ANTINEOPLASTIC AGENTS; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; THALIDOMIDE; TUMOR LYSIS SYNDROME;

EID: 1842555343     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdh116     Document Type: Letter

References (5)

1. Barlogie B, Desikan R, Eddlemon P, Spenser T, Zeldis J. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: Identification of prognostic factors in a phase 2 study of 169 patients. Blood 2001; 98: 492-494.
2. Cavenagh J, Oakervee H. Thalidomide in multiple myeloma: current status and future prospect. Br J Haematol 2003; 120: 18-26.
3. Grover JK, Uppal G, Raina V. The adverse effects of thalidomide in relapsed and refractory patients of multiple myeloma. Ann Oncol 2002; 13: 1636-1640.
4. Peuckmann V, Fisch M, Bruera E. Potential novel uses of thalidomide: Focus on palliative care. Drugs 2000; 60: 273-292.
5. Cany L, Fitoussi O, Boiron JM, Mart G. Tumor lysis syndrome at the beginning of thalidomide therapy for multiple myeloma. J Clin Oncol 2002; 20: 2212.